Goldcoasthealthplan Prior Authorization Lookup
Latest Goldcoasthealthplan prior authorization updates25
- Prior AuthClinical/Medical PolicyEff. 2026-09-03Religious Nonmedical Healthcare Institution (RNHCI)This policy governs coverage of medically necessary Medicare Part A inpatient and post-hospital services provided by a Medicare-certified Religious Nonmedical Healthcare Institution for eligible Gold Coast Health Plan Total Care Advantage beneficiaries. Coverage requires a valid RNHCI election, prior authorization, and satisfaction of applicable Medicare coverage requirements.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2026-05-14CYTOGAM (Cytomegalovirus Immune Globulin) for CMV Prophylaxis After TransplantationPrior authorization and Part B coverage of physician-administered CYTOGAM IV infusion for CMV disease prevention after kidney, lung, liver, pancreas, or heart transplantation, subject to specialist, dosing, administration-site, and duration requirements.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2026-05-14LOARGYS (pegzilarginase-nbln) for Arginase 1 DeficiencyThis policy governs prior authorization and Part B coverage of provider-administered LOARGYS for hyperargininemia associated with Arginase 1 Deficiency in adults and children age 2 years and older. Coverage includes dosing, administration, monitoring, documentation, and authorization requirements.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2026-05-14RYBREVANT and RYBREVANT FASPRO Coverage for EGFR-Mutated Non-Small Cell Lung CancerPrior authorization and Part B coverage criteria for physician-administered intravenous RYBREVANT and subcutaneous RYBREVANT FASPRO in adults with recurrent, advanced, or metastatic NSCLC and qualifying EGFR mutations.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2026-04-09Denosumab (Prolia, Xgeva, and Biosimilars) for Subcutaneous InjectionThis policy governs Part B coverage and prior authorization for physician-administered subcutaneous denosumab, including Prolia, Xgeva, and listed biosimilars, for Medicare Advantage members receiving treatment for osteoporosis, cancer-related fracture prevention, multiple myeloma or solid-tumor bone metastases, giant cell tumor of bone, or hypercalcemia of malignancy.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2026-02-12BLENREP (belantamab mafodotin-blmf) Coverage for Relapsed or Refractory Multiple MyelomaPrior authorization and Part B coverage for physician-administered intravenous BLENREP in adult members with relapsed or refractory multiple myeloma, including requirements for prior therapy, dosing, administration setting, documentation, monitoring, and authorization duration.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2026-02-12EYLEA, EYLEA HD, and PAVBLU (Aflibercept) Intravitreal InjectionsThis policy governs Part B coverage and prior authorization for physician-administered EYLEA, EYLEA HD, and PAVBLU intravitreal injections for specified retinal conditions in eligible adults and infants.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2026-02-12UNLOXCYT Coverage for Cutaneous Squamous Cell CarcinomaThis policy governs prior authorization and Part B coverage for physician-administered intravenous UNLOXCYT (cosibelimab-ipdl) in adults with metastatic or locally advanced cutaneous squamous cell carcinoma. It specifies clinical eligibility, dosing, administration settings, coding, authorization duration, and monitoring considerations.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2026-02-12Voraxaze (glucarpidase) Injection CoveragePart B coverage and prior authorization for provider-administered intravenous Voraxaze in adult and pediatric patients with toxic methotrexate concentrations and delayed clearance due to impaired renal function.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-11-13Emrelis (telisotuzumab vedotin-tllv) Coverage CriteriaThis policy governs prior authorization and Part B medical coverage for physician-administered intravenous Emrelis in adults with specified locally advanced or metastatic non-squamous non-small cell lung cancer. It establishes the covered indication, clinical approval criteria, dosing, administration setting, monitoring, and authorization duration.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-11-13KEBILIDI Coverage for Aromatic L-Amino Acid Decarboxylase DeficiencyThis policy governs prior authorization and Part B coverage for physician-administered KEBILIDI (eladocagene exuparvovec-tneq), an intraputaminal gene therapy for adult and pediatric patients with aromatic L-amino acid decarboxylase deficiency, including diagnostic, clinical, provider, age, dosing, safety, and one-time lifetime-use requirements.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-11-13LYNOZYFIC (linvoseltamab-gcpt) Coverage Criteria for Relapsed or Refractory Multiple MyelomaThis policy governs prior authorization and Part B coverage for physician-administered intravenous LYNOZYFIC in adults with relapsed or refractory multiple myeloma. It establishes FDA-indication requirements, prior-treatment history, dosing, monitoring, site-of-care, and documentation requirements.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-11-13ZIIHERA (zanidatamab-hrii) IV Therapy Coverage CriteriaThis policy governs Part B coverage and prior authorization for intravenous ZIIHERA in adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. It specifies the covered indication, dosing regimen, treatment duration, infusion timing, and billing identifiers.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Adakveo (crizanlizumab) Coverage CriteriaMedicare Part B prior authorization and coverage for Adakveo in patients aged 16 years and older with sickle cell disease, including indication, documentation, hydroxyurea step therapy, coding, dose, and coverage duration requirements.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Alyglo (immune globulin intravenous, human-stwk) Coverage CriteriaMedicare Part B prior authorization and coverage criteria for Alyglo in adults with primary humoral immunodeficiency, including documentation, dosing, coverage duration, and HCPCS billing requirements.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Benlysta IV (belimumab) Coverage CriteriaMedicare Advantage Part B coverage and prior authorization criteria for intravenous Benlysta in patients aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis receiving standard therapy.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Bivigam (immune globulin) Coverage CriteriaThis policy governs prior authorization and Medicare Part B coverage for Bivigam (immune globulin) administered intravenously. It applies to providers requesting coverage for eligible autoimmune, infectious, idiopathic, and other medically appropriate uses supported by the applicable Medicare LCD and medical records.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Boniva IV (ibandronate sodium) Coverage CriteriaThis policy governs prior authorization and Part B coverage of Boniva IV for osteoporosis in postmenopausal women. Supporting medical records and compliance with LCD L34648 are required.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Cinqair (reslizumab) Coverage CriteriaThis policy governs prior authorization and Part B coverage of Cinqair (reslizumab) for Medicare Advantage members with severe eosinophilic asthma requiring add-on therapy. It specifies covered use, clinical documentation, eosinophil thresholds, prescriber qualifications, exclusions, billing, and authorization duration.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Cinryze (C1 esterase inhibitor [human]) Coverage CriteriaMedicare Advantage Part B prior authorization and coverage for Cinryze used for routine prophylaxis against hereditary angioedema attacks in adults, adolescents, and children age 6 years and older.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Durysta (bimatoprost intraocular implant) CoverageThis policy governs prior authorization and Medicare Part B coverage for Durysta, a prostaglandin analog implant used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Providers must submit medical records documenting prior therapies and treatment response.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Evenity (romosozumab-aqqg) Coverage CriteriaThis policy governs prior authorization and Part B coverage of Evenity for osteoporosis in postmenopausal women at high risk for fracture or patients who have failed or cannot tolerate other osteoporosis therapies. It applies to providers requesting coverage under the Total Care Advantage Medicare Part B benefit.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Fasenra (benralizumab) Coverage CriteriaMedicare Part B coverage and prior authorization for Fasenra (benralizumab) used for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA), including clinical documentation, prescribing qualifications, dosing, and billing requirements.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Leqvio (inclisiran) Coverage CriteriaMedicare Advantage Part B prior authorization and coverage criteria for Leqvio in adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional LDL-C lowering.All goldcoasthealthplan updates
- Prior AuthClinical/Medical PolicyEff. 2025-08-21Nucala (mepolizumab) Coverage CriteriaThis policy governs Part B prior authorization and coverage criteria for Nucala (mepolizumab) for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. It applies to providers requesting initial coverage or reauthorization for eligible members.All goldcoasthealthplan updates
Tool Description
Search Goldcoasthealthplanprior authorization policies by drug name, procedure, or policy title. Results include any policy that mentions prior authorization requirements (drug coverage criteria, imaging guidelines, site-of-service rules) not just documents titled “prior authorization.” Every result links to a full policy page with clinical criteria, covered billing codes, documentation requirements, and effective dates.
Filter by payer, specialty, policy type, or effective year; or search directly for a drug (“Wegovy,” “Ozempic”), a procedure (“MRI,” “knee arthroplasty”), or a policy number.
Coverage spans 110+ payers. Jump straight to the busiest prior-auth publishers: UnitedHealthcare, Cigna, Aetna, Anthem, and Centene. You can also browse the full policy updates feed.
Pair a prior-auth search with the billing code lookup to confirm the CPT or J-code on the claim, the payer lookup for plan footprint, and payer profiles for contacts and coverage context.
FAQ
Prior Authorization by Payer
Go deeper
Explore OpenPayer Data
Prior auth requirements change all the time. Keep up with every payer policy update in the live policy feed, or browse payers with prior authorization policies.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Billing Code Reimbursement RatesBuild a reimbursement rate report across any mix of billing codes and states, comparing commercial payers against Medicare.
- Payer Comparison DashboardPick 2-5 payers to compare market share, premium, and membership by region, all at once.
- Facility Comparison DashboardPick 2-6 hospital facility types (or add a specific hospital) to compare facility count, revenue, net income, and Medicare/Medicaid payer mix by region, all at once.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Coverage Criteria LookupSearch payer coverage criteria and medical necessity requirements by drug, procedure, or payer.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.